Press "Enter" to skip to content

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

AstraZeneca and Merck & Co’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/pb7HyBt-96U/lynparza-stalls-pancreatic-cancer-in-patients-with-brca-mutations-study-idINKCN1T30EF

Also Read:   When hurricanes halt treatment, lung cancer patients die sooner